Studieoverzicht

Study name: Tropion-Lung 07

Histology NSCLC
Tumor stage Stage IV
Host / recruiting sites LUMC
Enrollment Recruiting
Therapy line First line (1L)
Design

Gerandomiseerde fase 3 studie

Intervention

Dato-DXd (Datopotamab Deruxtecan) icm Pembrolizumab vs Dato-DXd icm Pembrolizumab en platinum bevattende chemotherapie vs Pembrolizumab en platinum bevattende chemotherapie

Key outcome parameters

PFS, OS

Key inclusion criteria

Stadium IIIB-IV NSCLC zonder driver mutatie PD-L1 <50%, geen eerdere systeemtherapie

Key exclusion criteria

Symptomatische CNS metastasen

Co-morbiditeit oa LVEF <50%, ILD, equivalent >10mg prednison

Contact information